Tyme Technologies, Inc. announced that an open label phase II clinical trial evaluating SM-88 as a monotherapy in end-stage patients with advanced pancreatic cancer demonstrated substantially improved survival benefit compared to expected median overall survival outcomes. The 88-Panc open label phase II trial investigation involved 38 heavily pretreated patients with actively progressing metastatic pancreatic cancer who had received a median of two prior systemic therapies, and had significant disease related mortality. Researchers found that 68% of patients treated with SM-88, (19 of 28) remained alive after a median of 4.3 months of follow-up (median 5.8 months since completing prior treatment). Median survival has not been concluded for either evaluable or intent-to-treat (ITT) subjects with 60% of ITT subjects still alive. The survival data with SM-88 is significantly longer than published results in historical trials for comparable patients. SM-88 also demonstrated anti-tumor activity by computed topography (CT), positron emission topography (PET), and circulating tumor cell burden: 42% (8/17) stable disease or better at two-months under RECIST criteria, including 12% (2/17) with target lesion reductions of greater than 30%; 64% (7/11) stable disease or better at two-months using PET imaging, including reductions of up to 70%; 74% (16/23) with circulating tumor cell reductions of 30% or greater. The 88-Panc results are from an investigational study. SM-88 is not approved for the treatment of patients with advanced pancreatic cancer.